Today's Top 20 Stories
  1. Valeant's valuation overblown & more — 5 GI company key notes

    Here are five updates on GI companies from the past week:  By Eric Oliver -
  2. FDA approves Gilead's HCV treatment as 2nd line therapy — 4 insights

    The FDA approved Gilead Sciences' Vosevi as a second line therapy for chronic hepatitis C.  By Eric Oliver -
  3. Colorectal cancer treatment market to reach $5.03B by 2021 — 4 notes

    The colorectal cancer treatment market could reach $5.03 billion by 2021, growing at a compound annual growth rate of 2.21 percent from 2016 to 2021, according to Market Data Forecast analysis.  By Eric Oliver -

How to achieve positive patient identification

Sponsored
Learn tips and solutions for ensuring positive patient identification, EMPI integrity, and patient matching across systems.
  1. Dr. Vincent Galan: Pain management advancements shaping the ASC arena

    The healthcare market has witnessed advances in both surgical techniques and pain management, which have propelled surgeons to perform more cases in ASCs.  By Mary Rechtoris -
  2. 10 recommendations for managing workers' compensation claims in ASCs

    One of the most challenging claims for an ASC billing office to process are workers' compensation claims. It is equally challenging to provide universal recommendations to ease the process since workers' compensation claims regulations vary from state to state. Therefore, the most important recommendation is to know your specific state rules and regulations for billing workers' compensation.  By Angela Mattioda, Vice President of Revenue Cycle Management Services, Surgical Notes RCM -
  3. Avoiding 10 common billing mistakes that slow the ASC revenue cycle

    Effective revenue cycle management is the most important factor in maintaining the financial health of an ambulatory surgery center. The revenue cycle is comprised of several codependent processes that rely on both ASC software technology and billing expertise. The revenue cycle process begins with the capture of patient information at the time of scheduling. A complete solution also includes timely transcription services, precise coding, claims management, collections, managed care contracting, and strong business intelligence analytics. A mistake made at any point throughout the revenue cycle process can negatively impact a facility’s bottom line.  By Angela Mattioda, Vice President of Revenue Cycle Services, Surgical Notes RCM -
  4. Increased merger and acquisition activity in the ambulatory surgery center market … What does it all mean?

    Merger and acquisition activity in the ambulatory surgery center (ASC) arena has drastically increased in the past two years. This flurry of activity has left many in the ASC market wondering what this might mean for their centers, as well as what it might mean for the broader ASC market, in the upcoming years.  By Nader Samii, Chief Executive Officer, National Medical Billing Services -

The next generation of CRM

Sponsored
Learn how to improve patient engagement and population health management while proving ROI.
  1. Solutions for every setting — Gastroenterologist Dr. Michael DiMarino on the gMed™ suite

    Five years ago, Michael DiMarino, MD, of Woodbury, N.J.-based DiMarino-Kroop-Prieto Gastrointestinal Associates, began using gMed's products to assist with the value process. He reported he has never experienced such a simplified, user-friendly platform.  By Megan Wood -
  2. 3 key thoughts on ASC strategy today from Pacific Rim Outpatient Surgery Center's Gary Richberg

    Administrator of Bellingham, Wash.-based Pacific Rim Outpatient Surgery Center Gary Rihcberg, RN, discusses ASC leadership and strategy in the wake of uncertain healthcare reforms.  By Laura Dyrda -
  3. ASCA partners with translation, interpretation services: 5 things to know

    ASCA partnered with Akorbi, a translation and interpretation services platform.  By Laura Dyrda -
  4. Valeant to sell Obagi Medical Products business for $190M — 4 insights

    Valeant Pharmaceuticals agreed to sell its Obagi Medical Products skin care business for $190 million to Haitong International Zhonghua Finance Acquisition Fund I.  By Eric Oliver -
  1. How hospital ownership is changing: A CFO's thoughts on ASC, hospital relations

    Michael Walsh, CFO of Santa Cruz, Calif.-based Dominican Hospital, a Dignity Health Hospital, spoke with Becker's ASC Review about the evolving partnership between ASCs and hospitals as well as how hospitals can drive volume to surgery centers.  By Mary Rechtoris -
  2. UK hospital finds 27 missing contact lenses in cataract surgery patient

    United Kingdom-based Solihull Hospital medical staff found 27 missing contact lenses in the eye of a patient seeking cataract surgery, according to CNN.  By Mary Rechtoris -
  3. 10 most, least stressed US cities

    WalletHub compiled a list of the most and least stressed U.S. cities in 2017 using metrics including average weekly work hours and suicide rates.  By Mary Rechtoris -
  4. Former ASCA team member joins Association for Accessible Medicines: 3 things to know

    The Association for Accessible Medicines named Kristin Murphy director of federal affairs, according to Politico.  By Mary Rechtoris -
  5. Iowa physician suing state over CON law to appear before state council for 5th time: 4 key points

    Ophthalmologist Lee Birchansky, MD, will appear before Iowa's State Health Facilities Council regarding his proposal for an ASC in Cedar Rapids, Iowa.  By Mary Rechtoris -
  6. 5 key points on the New Jersey Association of Ambulatory Surgery Centers

    The New Jersey Association of Ambulatory Surgery Centers aims to promote and advance New Jersey ASCs' efforts in delivering high quality, cost-effective care.  By Mary Rechtoris -
  7. ASC leader to know: Larry Taylor of Practice Partners in Healthcare

    Larry Taylor is the founder of Practice Partners in Healthcare. He currently is the company's CEO and president.  By Mary Rechtoris -
  8. Last patient completes RedHill Biopharma's phase II study for IBS-D treatment — 4 insights

    RedHill Biopharma announced all enrolled patients completed treatment for the phase II study of its irritable bowel syndrome with diarrhea drug.  By Eric Oliver -
  9. Stock market week-in-review for 5 large GI companies — July 10-July 14

    Here is how five major, publicly traded gastroenterology companies fared in the stock market for the week of July 10 to July 14.  By Eric Oliver -

Featured Whitepapers

Webinars

Top 40 Articles from the Past 6 Months